Related references
Note: Only part of the references are listed.Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
Jie Lin et al.
CLINICAL CANCER RESEARCH (2013)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers
Chaitali Parikh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Targeting MET in cancer: rationale and progress
Ermanno Gherardi et al.
NATURE REVIEWS CANCER (2012)
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
Sarat Chandarlapaty et al.
CANCER CELL (2011)
Resistance of Akt kinases to dephosphorylation through ATP-dependent conformational plasticity
Tung O. Chan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
Hiroshi Hirai et al.
MOLECULAR CANCER THERAPEUTICS (2010)
The nuts and bolts of AGC protein kinases
Laura R. Pearce et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition
Wen-I Wu et al.
PLOS ONE (2010)
Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation
Kajsa Ericson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Inhibitor hijacking of Akt activation
Tatsuya Okuzumi et al.
NATURE CHEMICAL BIOLOGY (2009)
Role of a Novel PH-Kinase Domain Interface in PKB/Akt Regulation: Structural Mechanism for Allosteric Inhibition
Veronique Calleja et al.
PLOS BIOLOGY (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
Molecular Mechanism of an Oncogenic Mutation That Alters Membrane Targeting: Glu17Lys Modifies the PIP Lipid Specificity of the AKT1 PH Domain
Kyle E. Landgraf et al.
BIOCHEMISTRY (2008)
Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity
Nelson Rhodes et al.
CANCER RESEARCH (2008)
Use of Akt inhibitor and a drug-resistant mutant validates a critical role for protein kinase B/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake
Charlotte J. Green et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase
Dirk A. Heerding et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling
Qing-Bai She et al.
PLOS ONE (2008)
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
John D. Carpten et al.
NATURE (2007)
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
JA Engelman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
High-resolution structure of the pleckstrin homology domain of protein kinase B/Akt bound to phosphatidylinositol (3,4,5)-trisphosphate
CC Thomas et al.
CURRENT BIOLOGY (2002)
Share Paper
